• XCyton a Molecular Biology Company founded in 1993 by Dr. B.V. Ravi Kumar.
• XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. XCyton has developed Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System.
• XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens.
• XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of aetiological agents to a syndrome-based assessment which immediately enables physicians to make critical therapeutic decisions.
• Previously, XCyton has developed immunodiagnostic kits for the detection of infections.
• XCyton is credited with the development of the first indigenous ELISA kit for the detection of HIV infection called HIV CheX, following with the development of indigenous ELISA products for the detection of Hepatitis C (HEP CheX C), Neurocysticercosis (CYSTI CheX) and Japanese encephalitis (JEV CheX).